
CONSORT
TRANSPARENT REPORTING of TRIALS
Enrollment
Assessed for eligibility (n ~ 4,952)
Excluded (n ~ 4,916)
♦ not meeting inclusion criteria (n ~ 4,405)
Inclusion criteria defined as follows:
> 18 à + prophylactic LMWH therapy + acute kidney injury indicating CVVHD
♦ impaired hemostasis prior to or at time of ICU admission / start of CVVHD (n ~ 349)
- inherited or acquired coagulation disorder
- therapeutic anticoagulation prior to admission to ICU
- oral intake of platelet inhibitors
- major bleeding events indicating procoagulant medication prior to start of CVVHD
- severe liver dysfunction
♦ other reasons (e.g. patient`s refusal to participation; inclusion to another study; expected survival < 72hours; readmission and restart of CVVHD; CRRT other than CVVHD; CRRT devices other than multiFiltrate®) (n ~ 162)
Allocated to diagnostic test (n = 36)
Follow-Up
Lost to follow-up (n= 0)
Analysis
Analyzed (n= 26)
♦ Excluded from analysis due to start of therapeutic anticoagulation/platelet inhibition during CVVHD or due to missing TGA measurements (n = 10)